Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5 Venous Thrombosis 4 Venous Thromboembolism 2 Pulmonary Embolism 2 Thrombosis 1 Thromboembolism 1 Myeloproliferative Disorders 1

Interventions

Enoxaparin 4 Saline Solution 3 Warfarin 2 Tinzaparin 2 Dalteparin 2 Aspirin 2 enoxaparin sodium 1 edoxaban 1 alvocidib 1 Watchful Waiting 1 Tranexamic Acid 1 Sodium Chloride 1 Sodium Bicarbonate 1 Nadroparin 1 Lenalidomide 1 Ketoconazole 1 Immunoenzyme Techniques 1 High-Energy Shock Waves 1 Heparin, Low-Molecular-Weight 1 Heparin 1 Gemcitabine 1 Fondaparinux 1 Fluorodeoxyglucose F18 1 Fluoridation 1 Estramustine 1 Enzyme-Linked Immunosorbent Assay 1 Doxorubicin 1 Docetaxel 1 Clopidogrel 1 Bleeding Time 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Thromboembolism × edoxaban × Clear all

NCT04072068 2023-05-30

EDOI

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 4 Completed

Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡